Background: An ERTU/SITA fixed-dose combination is approved for the treatment of adults with type 2 diabetes mellitus (T2DM). As several SGLT2i + DPP-4i combinations are commercially available, MBMA of the HbA1c-lowering effect of these combinations was undertaken to assess their comparative effectiveness.
Methods: MBMA quantified the time course of dose vs. HbA1c response of SGLT2i + DPP-4i combinations and evaluated the impact of covariates including baseline HbA1c, estimated glomerular filtration rate (eGFR) and background diabetes treatment on HbA1c efficacy. Of the 496 randomized controlled trials (RCTs) in the database, 261 RCTs representing >87,000 T2DM patients were with SGLT2 inhibitors and/or DPP-4 inhibitors, including 2 RCTs for ERTU + SITA.
Results: For SGLT2i + DPP-4i combinations, the HbA1c efficacy increased with higher baseline HbA1c and decreased with declining renal function. Additionally, the HbA1c efficacy was greater on a diet background alone relative to a background of oral antidiabetic treatment.
Conclusion: This MBMA allowed an indirect comparison of SGLT2i + DPP-4i efficacy across trials (Table). Overall, ERTU 5 or 15 mg + SITA 100 mg doses were of comparable or numerically greater efficacy to other SGLT2i + DPP-4i combinations.
D. Fediuk: Employee; Self; Pfizer Inc. J. Mandema: Consultant; Self; Merck & Co., Inc., Pfizer Inc., Sanofi. K. Sweeney: Employee; Self; Pfizer Inc. S.G. Terra: Employee; Self; Pfizer Inc. V. Sahasrabudhe: Employee; Self; Pfizer Inc.
Pfizer Inc.; Merck Sharp & Dohme Corp.